Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer

Journal of Clinical Oncology

Volumn 20, Issue 17, 2002, Pages 3665-3673

  Modi, Shanu ^a   Panageas, Katherine S ^a   Duck, Elaine T ^a   Bach, Ariadne ^a   Weinstock, Nancy ^a   Dougherty, James ^a   Cramer, Laura ^a   Hudis, Clifford ^a   Norton, Larry ^a   Seidman, Andrew ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE ASSOCIATION; DRUG INFUSION; DRUG RESPONSE; HOSPITAL BILLING; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RATING SCALE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM METASTASIS; NEW YORK CITY; PACLITAXEL; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 0036727187     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.057     Document Type: Article

References (26)

1. Treatment of breast cancer
2. Quality of life in phase II trials: A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony stimulating factor
3. Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer
4. Economic considerations in comparing whole abdominal radiotherapy with combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: How much economic data should be collected?
5. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: Preliminary results from a randomized phase II clinical trial from Germany
6. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342
7. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
8. Final results: Randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients (pt) with met breast cancer - The long & short of it
9. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
10. The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics, and distress
11. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure
12. Reporting results of cancer treatment
13. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as frontline therapy in untreated metastatic breast cancer
14. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): An intergroup trial
15. Randomized trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: Quality of life evaluation using the EORTC QLQ-C 30 and Rotterdam Symptom Checklist
16. Doxorubicin (A)/Taxol (T) versus doxorubicin/cyclophosphamide (C) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study
17. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer
18. Biochemical modulation of fluorouracil: Evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma
19. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
20. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer
21. Quality-of-Life scores predict outcome in metastatic but not early breast cancer
22. Cost utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer
23. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients
24. Cost-utility analysis of taxane therapy
25. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer
26. A cost-utility analysis of second line chemotherapy in metastatic breast cancer